Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
03 Agosto 2023 - 12:30PM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced that
Sekar Kathiresan, M.D., co-founder and chief executive officer,
will present at the Canaccord 43rd Annual Growth Conference on
Thursday, August 10, 2023 at 11:30 a.m. ET in Boston.
A live webcast will be available in the investor section of the
company's website at www.vervetx.com. The webcast will be archived
for 30 days following the presentation.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s initial three programs – VERVE-101, VERVE-102, and
VERVE-201 – target genes that have been extensively validated as
targets for lowering low-density lipoprotein cholesterol (LDL-C), a
root cause of cardiovascular disease. VERVE-101 and VERVE-102 are
designed to permanently turn off the PCSK9 gene in the liver and
are being developed initially for heterozygous familial
hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic
cardiovascular disease (ASCVD) patients not at goal on oral
therapy. VERVE-201 is designed to permanently turn off the ANGPTL3
gene in the liver and is initially being developed for homozygous
familial hypercholesterolemia (HoFH) and ultimately to treat
patients with refractory hypercholesterolemia. For more
information, please visit www.VerveTx.com.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Giu 2023 a Giu 2024